New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 28, 2014
13:26 EDTTROWT. Rowe Price price target raised to $90 from $84 at Argus
Argus increased its price target on T. Rowe Price after the company reported stronger than expected Q1 results. The firm keeps a Buy rating on the shares.
News For TROW From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 26, 2014
16:18 EDTTROWT. Rowe urges Allergan to drop bid for Salix, has 'growing concern', FT says
T. Rowe Price (TROW), the third largest shareholder of Allergan (AGN), has urged the company to not partake in any acquisitions that would thwart Valeant's (VRX) hostile takeover plan, The Financial Times reports, citing senior business correspondent David Crow. Allergan is currently mulling the possibility of acquiring Salix Pharmaceuticals (SLXP), which may effectively squash Valeant's potential hostile takeover of Allergan. T. Rowe Price said in a statement, "Over the past several months, we have been watching with growing concern the corporate governance practices of the Allergan board. In our view, the issues to be voted on at the special meeting of shareholders on December 18 are of such importance that they impose a special duty on the board to refrain from approving any significant, irreversible commitments by the company between now and then unless shareholders are offered the opportunity to vote on them. We believe this should apply even in the event of all-cash acquisitions that do not ordinarily require a shareholder vote." Reference Link
September 22, 2014
08:51 EDTTROWT. Rowe Price should be owned into Q4, says Bernstein
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use